# Multidimensional repair of jujube pectic oligosaccharides on bone marrow hematopoietic failure

**Authors:** Hongxi Chen, BiYing Wang, XianZhen Li

PMC · DOI: 10.3389/fnut.2026.1734800 · Frontiers in Nutrition · 2026-01-29

## TL;DR

This study shows that jujube pectic oligosaccharides can help repair bone marrow damage and improve blood cell counts in a mouse model of myelosuppressive anemia.

## Contribution

The study reveals the therapeutic potential of Jujube Pectic Oligosaccharides (JOL) in treating myelosuppressive anemia through multi-target mechanisms.

## Key findings

- JOL administration restored multi-lineage peripheral blood cell counts in myelosuppressed mice.
- JOL improved structural integrity of the spleen and bone marrow.
- JOL modulated key hematopoietic factors like EPO, Flt3-L, TPO, and G-CSF.

## Abstract

Jujube, a valued resource in traditional practices for both medicine and diet, has been historically recognized for its blood-nourishing properties. Nevertheless, the potential of its active constituent, Jujube Pectic Oligosaccharides (JOL), to ameliorate myelosuppressive anemia remains poorly understood. This research was therefore designed to elucidate the therapeutic efficacy and underlying mechanism of JOL using a murine model of cyclophosphamide-induced myelosuppression. Our findings demonstrate that JOL administration effectively restored multi-lineage peripheral blood cell counts, improved the structural integrity of the spleen and bone marrow, and modulated key hematopoietic factors. These critical factors comprised erythropoietin (EPO), Flt3 ligand (Flt3-L), thrombopoietin (TPO), and granulocyte colony-stimulating factor (G-CSF). Collectively, the results indicate that Jujube oligosaccharides could mitigate myelosuppressive anemia via synergistic multi-target effects, possibly by rehabilitating the damaged hematopoietic microenvironment and normalizing the cytokine network equilibrium. This investigation offers foundational experimental support for the development of JOL as a promising therapeutic candidate for myelosuppression.

## Linked entities

- **Proteins:** EPO (erythropoietin), FLT3LG (fms related receptor tyrosine kinase 3 ligand), TPO (thyroid peroxidase), CSF3 (colony stimulating factor 3)
- **Chemicals:** cyclophosphamide (PubChem CID 2907), JOL (PubChem CID 172654923)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** myelosuppressive anemia (MESH:D000740), bone marrow hematopoietic failure (MESH:D000080983)
- **Chemicals:** oligosaccharides (MESH:D009844), JOL (-), cyclophosphamide (MESH:D003520)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12893996/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12893996/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12893996/full.md

---
Source: https://tomesphere.com/paper/PMC12893996